SuperworthUsana Health Sciences profit margin USNA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −2.4%
- Operating margin, 12 months
- −0.1%
- Net margin on a year earlier
- −6.2 pts
- Peer median
- 6.4%
Over the twelve months to Jul 4, 2026, Usana Health Sciences kept −2.4% of its revenue as net profit, with an operating margin of −0.1% and a gross margin of 77.4%.
Five years earlier its net margin was 11.1%.
The median for 8 chemicals stocks of a similar size is 6.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 1.2% | 4.0% | 78.3% |
| FY2024 | 4.9% | 7.8% | 81.1% |
| FY2023 | 6.9% | 10.1% | 80.8% |
| FY2022 | 6.9% | 10.8% | 80.6% |
| FY2021 | 9.8% | 14.3% | 81.6% |
| FY2020 | 11.0% | 15.6% | 81.6% |
| FY2019 | 9.5% | 13.8% | 82.3% |
| FY2018 | 10.6% | 15.8% | 83.1% |
| FY2017 | 6.0% | 12.7% | 82.9% |
| FY2016 | 9.9% | 13.8% | 82.1% |
| FY2015 | 10.3% | 15.4% | 82.6% |
| FY2014 | 9.7% | 14.7% | 82.2% |
| FY2013 | 11.0% | 16.3% | 82.3% |
| FY2012 | 10.2% | 15.1% | 82.1% |
| FY2011 | 8.7% | 13.3% | 82.5% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −2.4% | −6.2 pts | −0.1% | |
| Q1 FY26 | 1.0% | −3.0 pts | 3.8% | |
| Q4 FY25 | 1.2% | −3.8 pts | 4.0% | |
| Q3 FY25 | 1.9% | −4.4 pts | 4.6% | |
| Q2 FY25 | 3.8% | −2.5 pts | 6.2% | |
| Q1 FY25 | 4.0% | −2.9 pts | 6.5% | |
| Q4 FY24 | 4.9% | −2.0 pts | 7.8% | |
| Q3 FY24 | 6.3% | −0.1 pts | 9.6% | |
| Q2 FY24 | 6.3% | −0.4 pts | 9.6% | |
| Q1 FY24 | 6.9% | +0.2 pts | 10.1% | |
| Q4 FY23 | 6.9% | −0.0 pts | 10.1% | |
| Q3 FY23 | 6.4% | −1.0 pts | 9.9% |
Against its peers
Companies in Chemicals nearest Usana Health Sciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| USNAUsana Health Sciences | −2.4% |
| NAGENiagen Bioscience | 12.4% |
| FTLFFitlife Brands | 6.2% |
| FTKFlotek Industries | 13.0% |
| CRONCronos | 39.1% |
| BTMDbiote | 3.2% |
| ROGRogers | 3.7% |
| NGVTIngevity | 4.7% |
| IOSPInnospec | 6.6% |
| Peer median | 6.4% |
Where Usana Health Sciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Usana Health Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.